Reactive species promotion of head and neck squamous cell carcinoma
Abstract (Summary)
Head and neck squamous cell carcinoma (HNSCC), which comprises 3% of all of
the cancers in the U.S., is the most common form of oral cancer. The overall 5 year
survival rate is 59%, however, this disease is associated with high morbidity. Current
standard therapy involves surgical resection of the primary tumor followed by
radiotherapy and/or chemotherapy. Many of these tumors involve structures essential for
speech, taste, smell, breathing and eating. Surgical resection can compromise these
functions as well as leave the patient horribly disfigured. In addition, 3-7% patients per
year succumb to a second primary tumor at a related site as a complication of treatment.
While in the US this disease is regarded as a preventable cancer with low prevalence it is
the 8th most common cancer diagnosed in the world.
Clinical evidence supports a contribution of sustained inflammation, reactive
species (RS) and their sequelae in carcinogenesis. Studies in Chapter 2 focused on
elucidating mechanisms by which RS facilitate HNSCC tumorigenesis and included
evaluation of RS effects on sustained cell proliferation, induction of a proangiogenic
environment and increased growth factor production. Proinflammatory and
protumorigenic enzymes upregulated during inflammation include the RS-generating
enzymes inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2. While
ii
clinical data show upregulation of iNOS and COX-2 in HNSCC development,
mechanisms by which these cellular processes occur and downstream consequences have
not been characterized. The purpose of this investigation was to assess the effects of
reactive oxygen and nitrogen species on selected parameters of the HNSCC tumorigenic
phenotype i.e. nuclear factor (NF)?B activation, sustained cell proliferation, and
production of proinflammatory and proangiogenic proteins. RS donors included TNF,
H2O2, NOC18 and SIN1. NF?B activation was determined by in situ immunostaining
and reporter assay. Protein levels of VEGF, IL-8 and EGFR (determined by ELISA and
immunoblot) assessed downstream effects of NF?B activation. Results showed that
reactive oxygen (H2O2) and for the first time reactive nitrogen (SIN1) activated NF?B in
HNSCC cells. Notably, TNF, H2O2, NOC18 and SIN1 increased IL-8, VEGF and EGFR
protein levels. Our results indicate RS mediate HNSCC development by activation of
NF?B followed by increased growth factor production.
Much of cancer research focus is now directed towards the development of a new
generation of chemotherapeutics in an effort to prevent cancer. Chemoprevention refers
to the use of pharmacologic or natural compounds to either inhibit the invasive phenotype
of cancer by blocking progression of initiated cells, or by blocking or reversing
immortalization of cancer cells. Goals of chemoprevention therapy must address changes
at all levels of disease from clinical presentation to cellular and tissue levels.
N-acetyl-cysteine (NAC) has previously been identified as a potentially effective
chemopreventative agent. As a precursor to L-cysteine, the rate limiting reactant in
glutathione (GSH) synthesis, it possesses the innate ability to increase cellular stores of
the powerful antioxidant GSH, and inhibit consequences of RS. Matrix
iii
metalloproteinases (MMPs) are a family of enzymes noted for their ability to degrade the
extracellular matrix, which are activated by RS. Our laboratory recently determined a
mechanism by which NAC can inhibit the extracellular activation of MMP-9 by
preventing the cysteine switch step of activation. Their overexpression has been linked
to the ability of tumors to invade, metastasize and release growth factors bound to
proteins in the ECM.
Bibliographical Information:
Advisor:
School:The Ohio State University
School Location:USA - Ohio
Source Type:Master's Thesis
Keywords:mouth squamous cell carcinoma active oxygen intermediates chemistry epidermal growth factor interleukin 8 tumor necrosis vascular endothelial factors metalloproteinases nf kappa b dna binding protein
ISBN:
Date of Publication: